Abstract

Introduction The predictive accuracy of ARFI elastography (virtual touch quantification, VTq ™) for the non-invasive assessment of liver fibrosis is increasingly recognised, particularly in viral hepatitis. There is less information on its role in other aetiologies of chronic liver disease. We report the results of a preliminary study examining liver stiffness (LS) measurements by ARFI in patients with iron overload. Method Forty-nine measurements of LS in 43 patients were performed to investigate possible iron overload. LS estimation by ARFI was performed using a standard validated protocol with a Siemens Acuson S2000 + 4C1 probe. Biopsies were performed in 19 (39%) from the same region of liver, immediately after LS measurement. Clinical, biochemical, ultrasonic and histopathological data were collated retrospectively. Predictive accuracy variables were determined for fibrosis stage, using both standard published and local 1 calibrations. Results Aetiologies of iron overload in the biopsy cohort were: genetic haemochromatosis (n = 4); hyperferritinaemia with NAFLD or alcohol excess (8); hyperferritinaemia of unknown cause (3); transfusion-dependent thalassaemia (2); C282Y/H63D compound heterozygote (1); and high ferritin from renal cell carcinoma (1). Validation criteria for ARFI technical quality (SD/mean 1 ; b) the exclusion of ≥F2 fibrosis were 0.80, 0.78, 0.80 and 0.78, respectively, with both calibrations. No correlation was seen between LS and either a) necro-inflammation, histological grade of siderosis or scan technical quality; or b) serum ferritin levels. Conclusion ARFI elastography may prove a useful non-invasive technique for excluding F2 fibrosis and identifying F4 cirrhosis secondary to iron overload. The high incidence of dual pathology, particularly NAFLD and alcohol-related, may have influenced predictive accuracy in this small “real world” cohort. The degree of hepatic iron overload did not correlate with LS. Further biopsy-controlled studies are needed to validate the role of ARFI in this patient group. Disclosure of interest None Declared. Reference Sherman D, et al . J Hepatol. 2014;60(1):S413

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.